<p>在过去三个月中，4 位分析师对 Afya（纳斯达克：AFYA）发布了评级，提供了从看涨到看跌的多样化观点。</p>
<p>下表快速概述了他们最近的评级，突出了过去 30 天情绪的变化，并与前几个月进行了比较。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>分析师最近对 Afya 进行了评估，并提供了 12 个月的价格目标。平均目标为 18.0 美元，最高预估为 22.00 美元，最低预估为 16.00 美元。当前平均价格目标较之前的 19.75 美元下降了 8.86%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770987658_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="价格目标图表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770987658_0.png"/></p>
<h2>解读分析师评级：深入分析</h2>
<p>对最近分析师行动的深入分析揭示了金融专家对 Afya 的看法。以下总结概述了关键分析师、他们的最新评估以及对评级和价格目标的调整。</p>
<table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mauricio Cepeda</td>
<td>摩根士丹利</td>
<td>下调</td>
<td>低于大盘</td>
<td>$16.00</td>
<td>$17.50</td>
</tr>
<tr>
<td>Andre Salles</td>
<td>瑞银</td>
<td>下调</td>
<td>中性</td>
<td>$16.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Andre Salles</td>
<td>瑞银</td>
<td>下调</td>
<td>买入</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Marcelo Santos</td>
<td>摩根大通</td>
<td>下调</td>
<td>中性</td>
<td>$22.00</td>
<td>$24.50</td>
</tr>
</tbody>
</table>
<h3>关键见解：</h3>
<ul>
<li><strong>采取的行动：</strong> 针对市场动态和公司表现的变化，分析师更新他们的建议。无论是 “维持”、“上调” 还是 “下调” 他们的立场，都表明他们对与 Afya 相关的最新发展的反应。这为分析师对公司当前状态的看法提供了洞察。</li>
<li><strong>评级：</strong> 分析趋势时，分析师提供定性评估，范围从 “跑赢大盘” 到 “跑输大盘”。这些评级传达了对 Afya 相对于更广泛市场的表现预期。</li>
<li><strong>价格目标：</strong> 理解预测，分析师提供对 Afya 未来价值的估计。检查当前和之前的目标为分析师变化的预期提供了洞察。</li>
</ul>
<p>通过理解这些分析师评估及相关财务指标，捕捉 Afya 市场地位的宝贵见解。保持信息灵通，并通过我们的评级表做出战略决策。</p>
<p>随时了解 Afya 分析师评级。</p>
<p>如果您对跟踪小型股新闻和表现感兴趣，您可以从这里开始跟踪。</p>
<h2>关于 Afya</h2>
<p>Afya Ltd 是一家总部位于巴西的医学教育集团。其教育组合除了医学外，还包括管理、牙科、法律、工程、护理、心理学和会计科学等多个课程。它有三个业务板块；本科生通过与医学院相关的本科课程提供教育服务，本科健康科学和其他前健康本科项目，继续教育提供医学教育、专业化和医学研究生课程，通过数字和面对面的内容进行授课；医疗实践解决方案为医生提供临床决策、临床管理和医患关系，并为医疗参与者提供访问、需求和效率。</p>
<h3>Afya 的经济影响：分析</h3>
<p><strong>市值分析：</strong> 公司的市值低于行业基准，反映出与同行相比规模的缩小。这种定位可能受到增长预期或运营能力等因素的影响。</p>
<p><strong>收入增长：</strong> Afya 在过去三个月的表现显著。截至 2025 年 9 月 30 日，公司实现了 <strong>10.38%</strong> 的令人印象深刻的收入增长率。这标志着公司顶线收益的显著增加。与竞争对手相比，公司面临困难，增长率低于消费品行业同行的平均水平。</p>
<p><strong>净利润率：</strong> Afya 的净利润率超过行业标准，突显了公司的卓越财务表现。公司以 <strong>16.71%</strong> 的净利润率有效管理成本，实现强劲盈利。</p>
<p><strong>股本回报率（ROE）：</strong> Afya 的 ROE 低于行业平均水平，表明在有效利用股本方面可能面临挑战。ROE 为 <strong>3.32%</strong>，公司在实现最佳财务回报方面可能面临障碍。</p>
<p><strong>资产回报率（ROA）：</strong> Afya 的 ROA 低于行业标准，指向在有效利用资产方面的困难。ROA 为 <strong>1.68%</strong>，公司可能在从其资产中提供令人满意的回报方面遇到挑战。</p>
<p><strong>债务管理：</strong> Afya 的债务与股本比率为 <strong>0.63</strong>，低于行业平均水平，反映出对债务融资的依赖较低，采取了更为保守的财务策略。</p>
<h2>分析师评级是如何确定的？</h2>
<p>银行和金融系统的专家，分析师专注于特定股票或定义行业的报告。他们的全面研究包括参加公司电话会议和会议，分析财务报表，并与内部人士互动，以生成所谓的股票分析师评级。通常，分析师每季度评估和评级每只股票一次。</p>
<p>分析师可以通过纳入增长预估、收益和收入等指标的预测来增强他们的评估，为投资者提供额外的指导。重要的是要承认，尽管分析师在股票和行业方面是专家，但他们是人类，在提供见解时会表达他们的观点。</p>
<p>本文由 Benzinga 的自动内容引擎生成，并经过编辑审核。</p>

AFYA

<p>在过去三个月中，四位分析师对 Afya（NASDAQ:AFYA）进行了评级，显示出从看涨到看跌的情绪混合。12 个月的平均目标价为 18.00 美元，低于 19.75 美元，最高为 22.00 美元，最低为 16.00 美元。分析师们调整了他们的评级，一些人因市场动态而下调了目标价。Afya 是一家巴西医学教育集团，显示出 10.38% 的收入增长率，但在股本回报率和资产回报率方面面临挑战。其债务与股本比率低于行业平均水平，表明其采取了保守的财务策略</p>

<p>In the last three months, 4 analysts have published ratings on Afya (NASDAQ: AFYA), offering a diverse range of perspectives from bullish to bearish.</p>
<div class="lb-trans"><p>在过去三个月中，4 位分析师对 Afya（纳斯达克：AFYA）发布了评级，提供了从看涨到看跌的多样化观点。</p>
</div><p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<div class="lb-trans"><p>下表快速概述了他们最近的评级，突出了过去 30 天情绪的变化，并与前几个月进行了比较。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>Analysts have recently evaluated Afya and provided 12-month price targets. The average target is $18.0, accompanied by a high estimate of $22.00 and a low estimate of $16.00. Experiencing a 8.86% decline, the current average is now lower than the previous average price target of $19.75.</p>
<div class="lb-trans"><p>分析师最近对 Afya 进行了评估，并提供了 12 个月的价格目标。平均目标为 18.0 美元，最高预估为 22.00 美元，最低预估为 16.00 美元。当前平均价格目标较之前的 19.75 美元下降了 8.86%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770987658_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1770987658_0.png"/></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<div class="lb-trans"><h2>解读分析师评级：深入分析</h2>
</div><p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Afya. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>对最近分析师行动的深入分析揭示了金融专家对 Afya 的看法。以下总结概述了关键分析师、他们的最新评估以及对评级和价格目标的调整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mauricio Cepeda</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$16.00</td>
<td>$17.50</td>
</tr>
<tr>
<td>Andre Salles</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Andre Salles</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Marcelo Santos</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$24.50</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mauricio Cepeda</td>
<td>摩根士丹利</td>
<td>下调</td>
<td>低于大盘</td>
<td>$16.00</td>
<td>$17.50</td>
</tr>
<tr>
<td>Andre Salles</td>
<td>瑞银</td>
<td>下调</td>
<td>中性</td>
<td>$16.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Andre Salles</td>
<td>瑞银</td>
<td>下调</td>
<td>买入</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Marcelo Santos</td>
<td>摩根大通</td>
<td>下调</td>
<td>中性</td>
<td>$22.00</td>
<td>$24.50</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>关键见解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Afya. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Afya compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Afya's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>采取的行动：</strong> 针对市场动态和公司表现的变化，分析师更新他们的建议。无论是 “维持”、“上调” 还是 “下调” 他们的立场，都表明他们对与 Afya 相关的最新发展的反应。这为分析师对公司当前状态的看法提供了洞察。</li>
<li><strong>评级：</strong> 分析趋势时，分析师提供定性评估，范围从 “跑赢大盘” 到 “跑输大盘”。这些评级传达了对 Afya 相对于更广泛市场的表现预期。</li>
<li><strong>价格目标：</strong> 理解预测，分析师提供对 Afya 未来价值的估计。检查当前和之前的目标为分析师变化的预期提供了洞察。</li>
</ul>
</div><p>Capture valuable insights into Afya's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<div class="lb-trans"><p>通过理解这些分析师评估及相关财务指标，捕捉 Afya 市场地位的宝贵见解。保持信息灵通，并通过我们的评级表做出战略决策。</p>
</div><p>Stay up to date on Afya analyst ratings.</p>
<div class="lb-trans"><p>随时了解 Afya 分析师评级。</p>
</div><p>If you are interested in following small-cap stock news and performance you can start by tracking it here.</p>
<div class="lb-trans"><p>如果您对跟踪小型股新闻和表现感兴趣，您可以从这里开始跟踪。</p>
</div><h2>About Afya</h2>
<div class="lb-trans"><h2>关于 Afya</h2>
</div><p>Afya Ltd is a medical education group based in Brazil. Its education portfolio has several courses in addition to Medicine, such as Management, Dentistry, Law, Engineering, Nursing, Psychology, and Accounting Sciences, among others. It has three segments; Undergrad provides educational services through undergraduate courses related to medical school, undergraduate health science and other ex-health undergraduate programs, Continuing Education provides medical education, specialization and graduate courses in medicine, delivered through digital and in-person content; and Medical practice solution provides clinical decision, clinical management and doctor-patient relationships for physicians and provide access, demand and efficiency for the healthcare players.</p>
<div class="lb-trans"><p>Afya Ltd 是一家总部位于巴西的医学教育集团。其教育组合除了医学外，还包括管理、牙科、法律、工程、护理、心理学和会计科学等多个课程。它有三个业务板块；本科生通过与医学院相关的本科课程提供教育服务，本科健康科学和其他前健康本科项目，继续教育提供医学教育、专业化和医学研究生课程，通过数字和面对面的内容进行授课；医疗实践解决方案为医生提供临床决策、临床管理和医患关系，并为医疗参与者提供访问、需求和效率。</p>
</div><h3>Afya's Economic Impact: An Analysis</h3>
<div class="lb-trans"><h3>Afya 的经济影响：分析</h3>
</div><p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 公司的市值低于行业基准，反映出与同行相比规模的缩小。这种定位可能受到增长预期或运营能力等因素的影响。</p>
</div><p><strong>Revenue Growth:</strong> Afya's remarkable performance in 3M is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of <strong>10.38%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.</p>
<div class="lb-trans"><p><strong>收入增长：</strong> Afya 在过去三个月的表现显著。截至 2025 年 9 月 30 日，公司实现了 <strong>10.38%</strong> 的令人印象深刻的收入增长率。这标志着公司顶线收益的显著增加。与竞争对手相比，公司面临困难，增长率低于消费品行业同行的平均水平。</p>
</div><p><strong>Net Margin:</strong> Afya's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>16.71%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<div class="lb-trans"><p><strong>净利润率：</strong> Afya 的净利润率超过行业标准，突显了公司的卓越财务表现。公司以 <strong>16.71%</strong> 的净利润率有效管理成本，实现强劲盈利。</p>
</div><p><strong>Return on Equity (ROE):</strong> Afya's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>3.32%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<div class="lb-trans"><p><strong>股本回报率（ROE）：</strong> Afya 的 ROE 低于行业平均水平，表明在有效利用股本方面可能面临挑战。ROE 为 <strong>3.32%</strong>，公司在实现最佳财务回报方面可能面临障碍。</p>
</div><p><strong>Return on Assets (ROA):</strong> Afya's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>1.68%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<div class="lb-trans"><p><strong>资产回报率（ROA）：</strong> Afya 的 ROA 低于行业标准，指向在有效利用资产方面的困难。ROA 为 <strong>1.68%</strong>，公司可能在从其资产中提供令人满意的回报方面遇到挑战。</p>
</div><p><strong>Debt Management:</strong> Afya's debt-to-equity ratio is below the industry average at <strong>0.63</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<div class="lb-trans"><p><strong>债务管理：</strong> Afya 的债务与股本比率为 <strong>0.63</strong>，低于行业平均水平，反映出对债务融资的依赖较低，采取了更为保守的财务策略。</p>
</div><h2>How Are Analyst Ratings Determined?</h2>
<div class="lb-trans"><h2>分析师评级是如何确定的？</h2>
</div><p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<div class="lb-trans"><p>银行和金融系统的专家，分析师专注于特定股票或定义行业的报告。他们的全面研究包括参加公司电话会议和会议，分析财务报表，并与内部人士互动，以生成所谓的股票分析师评级。通常，分析师每季度评估和评级每只股票一次。</p>
</div><p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<div class="lb-trans"><p>分析师可以通过纳入增长预估、收益和收入等指标的预测来增强他们的评估，为投资者提供额外的指导。重要的是要承认，尽管分析师在股票和行业方面是专家，但他们是人类，在提供见解时会表达他们的观点。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自动内容引擎生成，并经过编辑审核。</p>
</div>

深入分析 Afya 股票：分析师的观点（4 个评级）